India is emerging as one of the most important long-term growth markets in medtech. With more than 1.4 billion people, a rapidly growing economy and increasing political focus on healthcare access, the direction is clear. The opportunity is significant, but it follows a different logic than most Western markets.
Adoption is shaped not only by clinical value, but by how technologies perform across highly diverse care settings and cost structures.
Not one market, but many entry points
India is often approached as a single market. In practice, it behaves like several.
The country consists of 28 states and 8 union territories, with major differences in healthcare access, infrastructure, purchasing power and system maturity. A strategy that works in urban centres like Mumbai or Bangalore will not translate to smaller cities or rural regions. For medtech companies, this means that market entry is not national, it is staged and selective.
Scaling in India rarely starts with broad rollout. It starts with choosing the right entry points.
How the system actually works
India’s healthcare system is best understood as a mix of overlapping logics rather than a single structure. The overlapping operating models behave differently depending on who is paying, where care is delivered and how access is structured.
Private hospitals tend to move faster but are highly focused on utilisation and return on investment. The public healthcare functions as a procurement-driven infrastructure layer. It offers scale but access is mediated through tenders, pricing pressure and administrative complexity. Alongside both sits a third force: the patient, who remains a direct economic actor due to significant out-of-pocket spending across much of the system.
Government schemes are expanding access. Programs such as Ayushman Bharat PM-JAY (informally referred to as “Modicare”), for example, provides public insurance coverage of up to ₹5 lakh per family per year (approximately €5,500–€6,000) for hospital care for large parts of the population. For medtech companies, this shapes where patient volume emerges and how pricing is constrained.
Yet despite these initiatives, India does not operate as a unified payer system. It functions as a fragmented reimbursement ecosystem, where pricing power, access pathways, and adoption dynamics vary significantly across geography, institution type, and funding source.
From fragmented care to scalable systems
While India’s healthcare system is still uneven in access, the system itself is evolving.
What was once a highly fragmented delivery landscape is gradually consolidating into more standardised, scalable and platform-oriented models of care. This shift is visible in the growing domestic medical manufacturing base, the rise of integrated healthcare platforms and a stronger focus on operational efficiency and discipline within hospital networks.
It is also reflected in how capital is being deployed. Investment is increasingly directed toward execution-heavy healthcare infrastructure, scalable service models and system-level operators, rather than early experimentation or isolated point solutions
For medtech companies, this signals a structural inflection point:India is no longer only absorbing technology at the margins, it’s beginning to standardise, industrialise and scale clinical innovation within its own operating system-
What actually drives adoption
In many Western healthcare systems, strong clinical performance and premium positioning are often sufficient to drive adoption. In India, the equation is different.
Here, the technologies are evaluated based on whether they can deliver value at scale, within tight cost constraints, variable infrastructure and heterogeneous care delivery environments.
Solutions that succeed tend to combine affordability with high utilisation, operational efficiency and robustness. They need to work across varying infrastructure levels and be reliably implemented and supported locally through training, service and distribution.
In this environment, credibility still matters, but it functions differently.European- and particularly Scandinavian medtech, is often associated with strong clinical quality and engineering standards. This can support early trust in pilot settings or with leading institutions. But it is rarely enough on its own. Trust may open doors, but system compatibility determines whether entry translates into scale.
Structural shifts shaping the market
India is becoming more accessible, but also more demanding in how value must be delivered.
Digital infrastructure has expanded rapidly, with over 1 billion internet users, supported by widespread 4G and 5G rollout and some of the lowest data costs globally. This creates a foundation for technologies such as AI diagnostics, remote monitoring and distributed care models to operate at population scale rather than niche deployment
At the same time, India is actively building domestic capacity. Through initiatives such as Make in India and Production Linked Incentives (PLI), the government is encouraging local manufacturing and long-term presence. Importing remains possible, but local value creation is increasingly rewarded.
Looking ahead, the upcoming EU–India Free Trade Agreement is expected to reduce tariff friction and improve regulatory predictability. However, it does not change the fundamental direction. India is becoming easier to enter, but not easier to win.
India as a healthcare hub
India is also taking on a broader role in the global healthcare landscape.
The country receives around 2 million international patients annually, particularly from Africa and other emerging markets. This is driven by a combination of clinical capability, shorter waiting times and cost advantages.
For medtech companies, this reinforces India’s role not only as a demand market, but as a setting where high-volume solutions are tested under real-world scale conditions. Technologies are exposed to diverse patient populations, variable infrastructure, and scaled clinical throughput earlier than in most Western markets.
What you need to do differently
Entering India requires a shift in mindset.
Companies that succeed tend to move from a margin-driven approach toward a volume-driven one, where scale and utilisation matter more than premium pricing. They prioritise system fit over product perfection, adapting to workflows, infrastructure and payment models rather than assuming transferability from other markets.
They also think regionally rather than nationally, starting in specific entry points such as regions, hospital clusters or care networks and expanding deliberately. Over time, many move beyond export into partnerships, service capability and local presence.
Most importantly, they focus on operational value. In India, solutions that improve efficiency, increase throughput or enable access often outperform those that only add clinical sophistication.
The bottom line
India is one of the most important future medtech markets, but it plays by different rules. It is shaped by scale, affordability, regional variation and a system that is evolving in real time.
The opportunity is not simply to bring innovation into India. The companies that succeed are those with the strongest understanding of how that technology works within the system.
This article is part of our series on commercialising medtech into global markets. Each article gives you a dive into one country - the landscape, real-world entry strategies, and the myths that cost companies time and money.
Served by Medtech Maze.
